Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Publication | Closed Access

DOI

142

Citations

References

2022

Year

Hartmut Goldschmidt, K. Elias, Uta Bertsch, Roland Fenk, Eva Nievergall, Diana Tichy, Britta Besemer, Jan Dürig, Roland Schroers, Ivana von Metzler,

The Lancet Haematology

Transplantation-eligible PatientsHematological MalignancyPart 1TransplantationMedicineImmunologyHematologyMultiple MyelomaPharmacotherapyOncologyCell TransplantationMyeloid Neoplasia